Subscribe to Search results

In 1975, radioimmunological assay began to be used with greater sensitivity, though it still missed around one third of infections.

Published on:

In 1975 Alter et al published "Clinical and serological analysis of transfusion-associated hepatitis" in The Lancet.

Published on:

The Acute Viral Hepatitis B: CDR Reports 1975-79 reported that outbreaks of Hepatitis B continued in the 1970s.

Published on:

The Sub-Committee on AIDS of the Cabinet Home and Social Affairs Committee agreed to make £10 million available to people with haemophilia infected with HIV by blood products.

Published on:

A grant of up to £10 million was provided to help people with haemophilia infected with HIV by blood products.

Published on:

A memo proposed that people without haemophilia infected with HIV through blood transfusions should also have a claim for financial assistance.

Published on:

The Secretary of State had been asked "to give some thought to the feasibility of adjusting his proposed definition of eligibility so as to include the few known cases of non-haemophiliacs infected with the AIDS virus by NHS treatment."

Published on:

The Secretary of State had decided not to extend the compensation scheme to cover other groups outside of people with haemophilia.

Published on:

Malcolm Harris (Assistant Secretary in HS1) agreed that the compensation scheme should not be extended to cover other groups outside of people with haemophilia.

Published on:

The Haemophilia Society published a press release about the Hepatitis C infection of many people with haemophilia and its urgent consideration of the matter.

Published on:

Gill Fyffe was unwell for seven years after her transfusion before she was identified as having been infected with Hepatitis C in the lookback in 1995.

Published on:

Dr George Galea said in oral evidence that ad-hoc lookback was being undertaken in late 1993 in Inverness. If a donor was found who had later tested positive for Hepatitis C, they would look back and see whether the blood taken was still in stock, whether it was transfused or sent to PFC.

Published on:

Dr Lorna Williamson said in oral evidence that letters regarding the lookback exercise were received by BTS in East Anglia on a Friday, and that the lookback was to start at the centre on Monday.

Published on:

Dr Patricia Hewitt said in oral evidence that she understood the decision not to undertake a UK-wide lookback exercise as soon as Hepatitis C testing became available in 1991 was a decision made by the Department of Health because no treatment could be offered.

Published on:

Dr Jack Gillon said in oral evidence that there was "no logic" in deciding not to conduct Hepatitis C lookback as soon as screening became available. His view was that even if there was no available treatment for Hepatitis C infection, individuals should be advised that they had a potentially serious condition.

Published on:

Dr Andrzej Rejman said in oral evidence that he could not recall discussion or an internal document within the Department of Health regarding commencing a Hepatitis C lookback when testing became available in the early 1990s.

Published on:

Professor Aileen Keel acknowledged in oral evidence that Scotland could have proceeded with a lookback exercise earlier than in the rest of the UK, however it did not. She said that it was "seen as desirable that in such an important area, that the whole of the UK did it roughly at the same time".

Published on:

A protocol for a pilot study to assess the introduction of routine anti-HCV tests in RTCs was drafted in November 1989 and carried out by Dr Gunson.

Published on:

The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted the policy regarding anti-Hepatitis C testing and that the focus should be on providing counselling services for those found to be anti-HCV positive.

Published on:

The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted the ACVSB agreed the anti-HCV test was a major step forward in identifying those who could transmit the virus, but that routine screening should not commence until the FDA had granted a license and that a cost benefit appraisal should be conducted and discussed with the Department of Health.

Published on: